Aventis Lantus/Amaryl Antidiabetic Pill-Shot Combo In Development
Executive Summary
Aventis is investigating its two approved antidiabetic agents in combination to improve glycemic control in patients with type 2 diabetes.
You may also be interested in...
Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn
Bristol plans to reallocate some of the money reserved for the launch of the antihypertensive Vanlev to help revive the cholesterol-lowering agent Pravachol.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials